AbbVie (ABBV) Announces EU Approval of RINVOQ as Oral Treatment for Adults with Active Non-Radiographic Axial Spondyloarthritis

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. SPY
3. META
4. ABBV
5. FDX
6. IBM
7. MU
8. PFE
9. AWK
10. ACN

Go back to AbbVie (ABBV) Announces EU Approval of RINVOQ as Oral Treatment for Adults with Active Non-Radiographic Axial Spondyloarthritis

RINVOQ® (upadacitinib) Approved by European Commission as an Oral Treatment for Adults with Active Non-Radiographic Axial Spondyloarthritis

July 29, 2022 2:00 AM EDT

With this approval, RINVOQ® (upadacitinib 15 mg, once daily) is the first and only Janus Kinase (JAK) inhibitor approved to treat patients across the spectrum of axial spondyloarthritis (nr-axSpA and ankylosing spondylitis) in the European Union (EU)1Approval is supported by data... More